Please login to the form below

Not currently logged in
Email:
Password:

Prostvac

This page shows the latest Prostvac news and features for those working in and with pharma, biotech and healthcare.

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

CV301 is Bavarian Nordic’s lead cancer vaccine after its much-delayed Prostvac candidate for prostate cancer failed to meet the mark in a phase III trial last year, wreaking havoc ... The setback was also a big disappointment for Bristol-Myers Squibb

Latest news

  • BMS signs $975m deal for Bavarian Nordic cancer vaccine BMS signs $975m deal for Bavarian Nordic cancer vaccine

    Furthermore, Bavarian Nordic could also receive regulatory milestone payments of $110m, up to $495m in sales milestones as well as tiered double-digit royalties on future sales of Prostvac. ... Analysts at Edison Research have predicted that Prostvac

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    Viral-vector based vaccines are also in the works. BN ImmunoTherapeutics and the US NCI are developing a viral-vector based vaccine, rilimogene galvacirepvec-rilimogene glafolivec (PROSTVAC), which is in phase

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics